Form 4 for BIIB Biogen
Accepted 2024-11-04 00:00:00 ET · period of report 2024-11-01 · accession 0001127602-24-026385 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-11-04 | 2024-11-01 | BIIB | Grogan Jane | Head of Research | M - OptEx | $0.00 | +695 | 695 | New | $0 |
| D | 2024-11-04 | 2024-11-01 | BIIB | Grogan Jane | Head of Research | F - Tax | $173.79 | -204 | 491 | -29% | -$35.5K |
| D | 2024-11-04 | 2024-11-01 | BIIB | Grogan Jane | Head of Research | M - OptEx | $0.00 | -695 | 1,390 | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-01 | M | A | 695 | $0.00 | 695 | D | — | — | |
| 2 | Common | Common Stock | 2024-11-01 | F | D | 204 | $173.79 | 491 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2024-11-01 | M | D | 695 | $0.00 | 1,390 | D | $0.00 · — to 2026-11-01 | 695 Common Stock | (F1) The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of November 1, 2023. |